Effects of the RANKL inhibitor, osteoprotegerin, on the pain and histopathology of bone cancer in rats

Clinical and Experimental Metastasis

Volumn 23, Issue 3-4, 2006, Pages 167-175

  Roudier, Martine P ^a,b   Bain, Steven D ^a   Dougall, William C ^b  

^a SkeleTech Inc   (United States)

^b AMGEN INC   (United States)

Author keywords

Animal; Bone neoplasms; Mammary neoplasms; Osteoprotegerin; Pain; RANK ligand; Rats

Indexed keywords

OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN;

ALLODYNIA; ANIMAL EXPERIMENT; ARTICLE; BONE CANCER; CANCER PAIN; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; NONHUMAN; OSTEOLYSIS; RAT; TUMOR VOLUME;

ANIMALS; BONE DENSITY; BONE NEOPLASMS; BONE RESORPTION; FEMALE; MAMMARY NEOPLASMS, EXPERIMENTAL; NEOPLASM TRANSPLANTATION; OSTEOPROTEGERIN; PAIN; RANK LIGAND; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS;

EID: 33750548635     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10585-006-9026-x     Document Type: Article

References (34)

1. Rubens RD (1998) Bone metastases - the clinical problem. Eur J Cancer 34(2):210-213
2. Mercadante S (1997) Malignant bone pain: pathophysiology and treatment. Pain 69(1-2):1-18
3. Schwei MJ, Honore P, Rogers SD et al (1999) Neurochemical and cellular reorganization of the spinal cord in a murine model of bone cancer pain. J Neurosci 19(24):10886-10897
4. Honore P, Rogers SD, Schwei MJ et al (2000) Murine models of inflammatory, neuropathic and cancer pain each generates a unique set of neurochemical changes in the spinal cord and sensory neurons. Neuroscience 98(3):585-598
5. Cain DM, Wacnik PW, Turner M et al (2001) Functional interactions between tumor and peripheral nerve: changes in excitability and morphology of primary afferent fibers in a murine model of cancer pain. J Neurosci 21(23):9367-9376
6. Medhurst SJ, Walker K, Bowes M et al (2002) A rat model of bone cancer pain. Pain 96(1-2):129-140
7. Clohisy DR, Mantyh PW (2004) Bone cancer pain and the role of RANKL/OPG. J Musculoskelet Neuronal Interact 4(3):293-300
8. Blair JM, Zhou H, Seibel MJ et al (2006) Mechanisms of disease: roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis. Nat Clin Pract Oncol 3(1):41-49
9. Lacey DL, Timms E, Tan HL et al (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93(2):165-176
10. Yasuda H, Shima N, Nakagawa N et al (1998) Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95(7):3597-3602
11. Burgess TL, Qian Y, Kaufman S et al (1999) The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol 145(3):527-538
12. Hsu H, Lacey DL, Dunstan CR et al (1999) Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 96(7):3540-3545
13. Kong YY, Yoshida H, Sarosi I et al (1999) OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis. Nature 397:315-323
14. Lacey DL, Tan HL, Lu J et al (2000) Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am J Pathol 157(2):435-448
15. Simonet WS, Lacey DL, Dunstan CR et al (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89(2):309-319
16. Udagawa N, Takahashi N, Yasuda H et al (2000) Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function. Endocrinology 141:3478-3484
17. Urch C (2004) The pathophysiology of cancer-induced bone pain: current understanding. Palliat Med 18(4):267-274
18. Lipton A, Ali SM, Leitzel K et al (2002) Serum osteoprotegerin levels in healthy controls and cancer patients. Clin Cancer Res 8(7):2306-2310
19. Terpos E, Szydlo R, Apperley JF et al (2003) Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood 102(3):1064-1069
20. Grimaud E, Soubigou L, Couillaud S et al (2003) Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis. Am J Pathol 163(5):2021-2031
21. Capparelli C, Morony S, Warmington K et al (2003) Sustained antiresorptive effects after a single treatment with human recombinant osteoprotegerin (OPG): a pharmacodynamic and pharmacokinetic analysis in rats. J Bone Miner Res 18:852-858
22. Clohisy DR, Ramnaraine ML, Scully S et al (2000) Osteoprotegerin inhibits tumor-induced osteoclastogenesis and bone tumor growth in osteopetrotic mice. J Orthop Res 18(6):967-976
23. Morony S, Capparelli C, Sarosi I et al (2001) Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res 61(11):4432-4436
24. Honore P, Luger NM, Sabino MA et al (2000) Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. Nat Med 6(5):521-528
25. Luger NM, Honore P, Sabino MA et al (2001) Osteoprotegerin diminishes advanced bone cancer pain. Cancer Res 61(10):4038-4047
26. Chaplan SR, Bach FW, Pogrel JW et al (1994) Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 53(1):55-63
27. Olson TH, Riedl MS, Vulchanova L et al (1998) An acid sensing ion channel (ASIC) localizes to small primary afferent neurons in rats. Neuroreport 9(6):1109-1113
28. Li Y, Kucuk O, Hussain M et al (2006) Antitumor and antimetastatic activities of docetaxel are enhanced by genistein through regulation of osteoprotegerin/receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/MMP-9 signaling in prostate cancer. Cancer Res 66(9):4816-4825
29. Body JJ, Facon T, Coleman RE et al (2006) A study of the biologic RANKL inhibitor, denosumab (AMG 162), in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 12(4):1221-1228
30. Li EC, Davis LE (2003) Zoledronic acid: a new parenteral bisphosphonate. Clin Ther 25(11):2669-2708
31. Walker K, Medhurst SJ, Kidd BL et al (2002) Disease modifying and anti-nociceptive effects of the bisphosphonate, zoledronic acid in a model of bone cancer pain. Pain 100(3):219-229
32. Bonabello A, Galmozzi MR, Canaparo R et al (2003) Long-term analgesic effect of clodronate in rodents. Bone 33(4):567-574
33. Sevcik MA, Luger NM, Mach DB et al (2004) Bone cancer pain: the effects of the bisphosphonate alendronate on pain, skeletal remodeling, tumor growth and tumor necrosis. Pain 111(1-2):169-180
34. Goicoechea C, Porras E, Alfaro MJ et al (1999) Alendronate induces antinociception in mice, not related with its effects in bone. Jpn J Pharmacol 79(4):433-437